诊断用酵素的全球市场:现状分析、预测(2022年～2028年)

全球诊断用酵素的市场规模，由于诊断技术的创新高涨，及酵素为基础的诊断检验的采用持续增加，预计以约4％稳定成长。还有各种感染疾病和慢性疾病的盛行率上升，是诊断用酵素市场的主要成长促进因素之一。

本报告提供全球诊断用酵素市场相关调查分析，各市场区隔、各地区的市场洞察，市场动态，市场趋势，竞争情形，企业简介等系统性资讯。

目录

第1章 市场简介

第2章 调查手法、前提条件

第3章 市场概要

第4章 摘要整理

第5章 COVID-19对诊断用酵素市场的影响

第6章 诊断用酵素市场收益(2020年～2028年)

第7章 市场洞察:各类型

• Taq聚合酵素
• RNase抑制剂
• Cas9酵素
• 酸性磷酸酶
• 葡萄糖氧化酵素/葡萄糖去氢酵素
• 尿素酶
• 乳酸氧化酶
• 其他

第8章 市场洞察:各用途

• 感染疾病
• 自体免疫疾病
• 肿瘤学
• 心臟病
• 肾臟学
• 糖尿病
• 其他

第9章 市场洞察:各产品类型

• 分子酵素
• 临床酵素

第10章 市场洞察:各终端用户

• 医院
• 临床检验室
• 其他

第11章 市场洞察:各地区

• 北美
  • 美国
  • 加拿大
  • 其他北美
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他欧洲
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 其他地区

第12章 诊断用酵素:市场动态

• 推动市场要素
• 市场课题
• 影响分析

第13章 诊断用酵素:市场机会

第14章 诊断用酵素:市场趋势

第15章 需求侧、供给侧的分析

• 需求面分析
• 供给侧分析

第16章 价值链分析

第17章 竞争模式

• 竞争情形
  • 波特的五力分析

第18章 企业概要

• Takara Bio, Inc.
• Promega Corporation
• Enzo Life Sciences, Inc.
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Creative Enzymes
• F. Hoffmann-La Roche Ltd.
• Solis BioDyne
• Ampliqon A/S
• Genzyme Corporation

第19章 免责声明

Enzymes are proteins with highly specialized catalytic functions, produced by all living organisms. The metabolic activity of all living creatures, including plants, microbes, animals, and mankind, depends on enzymes. Because of their excellent bio-catalytic properties, enzymes are frequently used in the detection of numerous disorders. Several metabolic problems can be caused by enzyme abnormalities. As a result, elements of the enzyme metabolism systems have been used as unique markers for the diagnosis of diseases. The prompt control of the transmission of infectious diseases and the reduction of the dangers to public health depends on the adoption of proper diagnostic enzyme techniques. Therefore, the rising prevalence of various infectious & chronic diseases is one of the major factors responsible for the growth of the diagnostic enzymes market. For instance, as per the World Health Organization 2020, the global impact of infectious disease by the SARS-CoV-2 outbreak (COVID-19), caused over 13.3 million infections and 782,000 deaths globally.

The Diagnostic Enzymes Market is expected to grow at a steady rate of around 4% owing to the increasing adoption of enzyme-based diagnostic tests coupled with the growing innovations in diagnostics technologies. Major players in the market offer innovative developments in the biotechnology domain with technologically advanced features. For instance, in January 2021, Creative Enzymes launched a complete product portfolio of diagnostic enzymes for medical and research diagnosis.

Based on type, the diagnostic enzymes market is segmented into Taq polymerase, RNase inhibitors, cas9 enzyme, acid phosphatase, glucose oxidase/glucose dehydrogenase, urease, lactate oxidase, and others. The glucose oxidase/glucose dehydrogenase segment accounted for a significant market share in 2020 owing to its several advantages such as its abundance, biocompatibility, and lack of toxicity. Furthermore, the entry of global players into emerging markets adds to the growth of the market during the forecast period.

On the basis of application, the diagnostic enzymes market is segmented into infectious diseases, autoimmune diseases, oncology, cardiology, nephrology, diabetes, and others. Among these, the infectious diseases segment to hold a significant share of the market in 2020. This is mainly due to the rising incidence of infectious diseases, that require early detection using these enzymes. For instance, according to the CDC/National Center for Health Statistics, 2022, the number of emergency department visits with infectious and parasitic diseases as the primary diagnosis in the US was 3.4 million. Therefore, infectious diseases such as typical pneumonia, TB, streptococcal pharyngitis, ulcerative urogenital infections, and a number of chronic conditions can be easily diagnosed with enzyme-based techniques like PCR.

Based on product type, the diagnostic enzymes market has been classified into molecular enzymes and clinical enzymes. The molecular enzymes category holds a major share of the market during the forecast period. This is mainly due to the rising research and adoption of molecular enzymes in molecular diagnostics. Different enzymes are mostly used through methods like PCR tests, NGS assays, and others. One of the most used molecular biology methods is PCR. The technology is being used more and more in a variety of industries, such as cloning, sequencing, forensic investigation, and diagnostic testing.

For a better understanding of the market adoption of the Diagnostic Enzymes industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the increased need for enzymes and the rising incidence of infectious diseases in the region which has become dominant. In order to combat the continuing epidemic, the FDA has approved COVID-19 laboratory-developed diagnostics for emergency use. The majority of these emergency usage authorizations also make use of RT-PCR-based testing and enzyme-linked immunosorbent assays for the identification of SARS-CoV-2. The creation of such tests is anticipated to be profitable in the North American market because of the high usage of enzymes during RT-PCR.

Some of the major players operating in the market include: Takara Bio, Inc., Promega Corporation, Enzo Life Sciences, Inc., Merck KGaA, Thermo Fisher Scientific, Inc., Creative Enzymes, F. Hoffmann-La Roche Ltd., Solis BioDyne, Ampliqon A/S, and Genzyme Corporation

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Diagnostic Enzymes Market
• 2.2. Research Methodology of the Diagnostic Enzymes Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE DIAGNOSTIC ENZYMES MARKET

6 DIAGNOSTIC ENZYMES MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY TYPE

• 7.1. Taq Polymerase
• 7.2. RNase Inhibitors
• 7.3. Cas9 Enzyme
• 7.4. Acid Phosphatase
• 7.5. Glucose Oxidase/Glucose Dehydrogenase
• 7.6. Urease
• 7.7. Lactate Oxidase
• 7.8. Others

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Infectious Diseases
• 8.2. Autoimmune Diseases
• 8.3. Oncology
• 8.4. Cardiology
• 8.5. Nephrology
• 8.6. Diabetes
• 8.7. Others

9 MARKET INSIGHTS BY PRODUCT TYPE

• 9.1. Molecular Enzymes
• 9.2. Clinical Enzymes

10 MARKET INSIGHTS BY END USERS

• 10.1. Hospitals
• 10.2. Clinical Laboratories
• 10.3. Others

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. U.S.
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. U.K.
  • 11.2.3. France
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia-Pacific
  • 11.3.1. China
  • 11.3.2. Japan
  • 11.3.3. India
  • 11.3.4. Rest of Asia-Pacific
• 11.4. Rest of World

12 DIAGNOSTIC ENZYMES MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 DIAGNOSTIC ENZYMES MARKET OPPORTUNITIES

14 DIAGNOSTIC ENZYMES MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porters Fiver Forces Analysis

18 COMPANY PROFILED

• 18.1. Takara Bio, Inc.
• 18.2. Promega Corporation
• 18.3. Enzo Life Sciences, Inc.
• 18.4. Merck KGaA
• 18.5. Thermo Fisher Scientific, Inc.
• 18.6. Creative Enzymes
• 18.7. F. Hoffmann-La Roche Ltd.
• 18.8. Solis BioDyne
• 18.9. Ampliqon A/S
• 18.10. Genzyme Corporation

19 DISCLAIMER